Novya Biotech

Driven by the growing demand for innovative therapeutics and the efficient production of complex pharmaceutical compounds, the precision fermentation market—where yeast is used as a sustainable production platform—is projected to exceed $20 billion within five years, with a staggering CAGR of 43.2% through 2030. Despite this rapid growth, developing a profitable yeast-based production system remains a significant challenge. Current approaches rely on step-by-step DNA modifications, exploring countless possibilities without clear guidance on which genetic changes will lead to success.

Novya Biotech addresses these challenges with a proprietary platform that revolutionizes strain engineering. By leveraging yeast’s sexual reproduction cycle and integrating CRISPR-Cas technology, our platform enables precise, modular genetic modifications that can be stacked exponentially faster than traditional methods. This breakthrough dramatically reduces development time and costs: we can do in months what used to take years, even decades.

Our business model combines R&D services, providing exclusive engineered yeast strains and creating a portfolio of generic improved production strains, tailored for a broader need. Such a portfolio will create scalable revenue streams while our adaptable platform enables the efficient reuse of beneficial traits across projects, maximizing value. Long-term, we aim to expand our platform to other yeast species and engineer strains that can create novel “new-to-nature” molecules.

With proof-of-concept studies, patent protections, and support from Wageningen University & Research and Utrecht Inc, Novya Biotech is strategically positioned for long-term growth. Operating in a rapidly expanding market that values sustainable and innovative solutions, our team of CRISPR-Cas, biotechnology, and yeast experts is driving transformative innovation across industries.